

IN THE CLAIMS

1. (Previously Presented) A multivalent meningococcal bleb composition comprising a first bleb preparation deficient in PorA, wherein the first bleb preparation is derived from the *Neisseria meningitidis* B CU-385 strain, and a second bleb preparation that is not deficient in PorA, wherein the second bleb preparation is derived from a *Neisseria meningitidis* B:4:P1.7b, 4 strain prevalent in New Zealand.

2-5. (Cancelled)

6. (Previously Presented) A vaccine for protection against *Neisseria meningitidis* infection comprising the multivalent meningococcal bleb composition of Claim 1, and a pharmaceutically acceptable excipient.

7. (Previously Presented) The vaccine of Claim 6 additionally comprising one or more plain or conjugated meningococcal capsular polysaccharides selected from the group of serogroups: A, C, Y and W.

8-10. (Cancelled)

11. (Withdrawn) A method of manufacturing the multivalent meningococcal bleb composition of Claim 1 comprising the step of combining the first bleb preparation and the second bleb preparation.

12. (Withdrawn) A method of preventing neisserial-disease comprising the step of administering an immunologically effective amount of the vaccine of Claim 6 to a host in need thereof.

13. (Withdrawn) The use of an immunologically effective amount of the vaccine of Claim 6 in the manufacture of a medicament for the prevention neisserial disease.

14. (Withdrawn) A method of manufacturing the vaccine of Claim 6 comprising the step of combining the first bleb preparation and the second bleb preparation.

15. (Cancelled)

16. (New) A vaccine for protection against *Neisseria meningitidis* infection, said vaccine consists of wherein the first bleb preparation is derived from the *Neisseria meningitidis* B CU-385 strain, and a second bleb preparation that is not deficient in PorA, wherein the second bleb preparation is derived from a *Neisseria meningitidis* B:4:P1.7b, 4 strain prevalent in New Zealand, and a pharmaceutically acceptable excipient.